FINWIRES · TerminalLIVE
FINWIRES

$LSTA

3 stories mentioning LSTAUpdated 50d ago

Every FINWIRES story that references LSTA, newest first.

What are analysts saying about LSTA?

Recent broker actions mentioned in FINWIRES coverage. Compiled from wire headlines; not investment advice.

What's the latest news on LSTA?

Sectors

Sector Update: Healthcare Stocks Higher Late Afternoon

Healthcare stocks rose late Friday afternoon, with the NYSE Healthcare Index up 0.6% and the State Street Health Care Select Sector SPDR ETF (XLV) adding 0.7%.The iShares Biotechnology ETF (IBB) decreased 0.3%.In corporate news, Tenet Healthcare (THC) shares surged past 17% after it posted higher Q2 adjusted earnings and revenue, and raised its 2026 guidance.Novo Nordisk (NVO) is seeking a preliminary US court injunction to immediately block advertising by Eli Lilly (LLY) for its obesity and diabetes drugs, escalating the companies' legal dispute over weight-loss drug marketing, Reuters reported Friday. Novo shares rose 1.9%, and Lilly was up 0.6%.Profound Medical (PROF) said new data from a Level 1 evidence trial of its MRI-guided Tulsa procedure demonstrated statistically significant superiority over robotic radical prostatectomy in men with intermediate-risk prostate cancer. Its shares jumped past 8%.Lisata Therapeutics (LSTA) shares fell 16% after the company said it has terminated its planned merger with Kuva Labs.

$LLY$LSTA$NVO$PROF$THC
Wire

Lisata Therapeutics Shares Fall After Terminating Kuva Labs Deal

Lisata Therapeutics (LSTA) shares were down about 17% in Friday afternoon trading after the company said it has terminated its previously announced proposed merger with Kuva Labs.Lisata was informed that Kuva Labs failed to secure sufficient funding to fulfill the tender offer to acquire all of Lisata's outstanding shares, the company said in a Friday filing.As a result of the termination, Lisata said it is entitled to a fee of $2 million and has the right to seek damages, but there is no assurance it will be able to obtain damages due to its limited funds for litigation and Kuva Labs' inability to satisfy its claims with its existing assets.Price: $1.77, Change: $-0.35, Percent Change: -16.51%

$LSTA
Research

HC Wainwright Downgrades Lisata Therapeutics to Neutral From Buy

HC Wainwright Downgrades Lisata Therapeutics to Neutral From Buy

$LSTA

Track with the FINWIRES app suite